| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
SF-11 targets the neuropeptide Y Y2 receptor (NPY Y2). It is a potent and selective NPY Y2 receptor antagonist with an IC₅₀ of 199 nM. It displays no affinity for Y1 receptor at concentrations up to 35 μM. Radioligand studies reveal that SF-11 also targets 5-HT2B and dopamine transporter. The compound is brain-penetrant.
|
|---|---|
| ln Vitro |
In vitro, SF-11 is a potent and brain penetrant neuropeptide Y Y2 receptor antagonist with an IC₅₀ of 199 nM. It displays no affinity for Y1 receptor at concentrations up to 35 μM. Radioligand studies reveal that SF-11 also targets 5-HT2B and dopamine transporter. The compound exhibits antidepressant-like activity.
|
| ln Vivo |
In vivo, SF-11 exhibits antidepressant-like activity. It causes significant lethality in mice. The compound is brain-penetrant. It is used in NPY Y2 receptor-mediated studies. However, specific in vivo efficacy data in animal models are not detailed in the available literature.
|
| Enzyme Assay |
The in vitro receptor binding assay for SF-11 involves measuring its binding affinity to the neuropeptide Y Y2 receptor. This is typically done using radiolabeled ligand competition assays on cells expressing Y2 receptors. The IC₅₀ of 199 nM is determined by quantifying the reduction in radioligand binding. Radioligand studies also assess binding to 5-HT2B and dopamine transporter.
|
| Cell Assay |
In vitro cell-based assays for SF-11 involve treating cells expressing NPY Y2 receptors with the compound and measuring downstream signaling events, such as cAMP modulation or calcium influx. The compound's antagonist activity is assessed by its ability to block Y2 receptor-mediated responses.
|
| Animal Protocol |
In vivo animal studies for SF-11 involve administering the compound to rodents and measuring its effects on behavior, such as antidepressant-like activity. The compound's brain penetration and lethality in mice are also assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of SF-11 are not extensively detailed in the available literature. The compound is brain-penetrant. It is soluble in DMSO: 250 mg/mL (559.79 mM; Need ultrasonic). For storage, powder should be kept at 4°C, protected from light; in solvent at -80°C for 6 months or -20°C for 1 month (protect from light).
|
| Toxicity/Toxicokinetics |
No specific toxicity data for SF-11 are available in the provided literature. It causes significant lethality in mice. The compound is for research use only and not for human therapeutic applications. Standard laboratory safety precautions should be followed when handling.
|
| References | |
| Additional Infomation |
N-(4-ethoxyphenyl)-4-[hydroxy(diphenyl)methyl]-1-piperidinethiocarboxamide is a diarylmethane.
SF-11 is a potent, brain-penetrant neuropeptide Y Y2 receptor antagonist. It exhibits antidepressant-like activity. It also targets 5-HT2B and dopamine transporter. It is for research use only. Its CAS number is 443292-81-7. |
| Molecular Formula |
C27H30N2O2S
|
|---|---|
| Molecular Weight |
446.6043
|
| Exact Mass |
446.203
|
| CAS # |
443292-81-7
|
| PubChem CID |
2936384
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.441
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
554
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PMEQBGAGFZDWQX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H30N2O2S/c1-2-31-25-15-13-24(14-16-25)28-26(32)29-19-17-23(18-20-29)27(30,21-9-5-3-6-10-21)22-11-7-4-8-12-22/h3-16,23,30H,2,17-20H2,1H3,(H,28,32)
|
| Chemical Name |
N-(4-ethoxyphenyl)-4-[hydroxy(diphenyl)methyl]piperidine-1-carbothioamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~559.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2391 mL | 11.1957 mL | 22.3914 mL | |
| 5 mM | 0.4478 mL | 2.2391 mL | 4.4783 mL | |
| 10 mM | 0.2239 mL | 1.1196 mL | 2.2391 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
